Premium
Mass spectrometry‐based metabolomics as a unique biochemical approach for understanding disease pathogenesis (350.3)
Author(s) -
Siuzdak Gary
Publication year - 2014
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.28.1_supplement.350.3
Subject(s) - metabolomics , metabolome , computational biology , context (archaeology) , metabolite , proteome , genomics , biology , disease , proteomics , bioinformatics , genome , biochemistry , medicine , gene , pathology , paleontology
Metabolomics, the quantitative global analysis of endogenous metabolites from cells, tissues, fluids and whole organisms, is becoming an integral part of functional genomics efforts as well as a tool for understanding fundamental biochemistry. While the genome and proteome represent upstream biochemical events, metabolites correlate with the most downstream biochemistry and therefore most closely represent the phenotype. This has been proven by the broad success of metabolite analysis in clinical diagnostics. The experimental aim in our studies is to obtain a comprehensive quantitative view of the metabolome to expand our understanding of what pathways are altered in specific diseases. We have developed a novel mass spectrometry platform for metabolomics including XCMS Online data analysis combined with METLIN, a comprehensive MS/MS metabolite database. As well as nanostructure‐initiator mass spectrometry (NIMS) imaging. These technologies will be presented in the context of their application to discovering new disease therapies/pathways for chronic pain and cancer.